CHRONIX BIOMEDICAL, INC

Chronix Biomedical, Inc. is a molecular diagnostics company offering laboratory developed blood tests to doctors for cancer screening supplemental evaluations and monitoring cancer through its own certified laboratories. Chronix is privately held with headquarters in San Jose, California, and laboratories in Göttingen, Germany. Currently, Chronix Biomedical is offering 4 different tests.

stethoscope

Delta Dot treatment outcome evaluation test

A blood test that indicates whether a treatment is working in one to two cycles of therapy with over 90% positive predictive value.

microscope

CNI cancer evaluation
test

A blood test that reveals mutations mostly seen in patients with cancer.

heart

Second Opinion™ prostate cancer evaluation test

A blood test for men with elevated PSA that reveals the mutations mostly seen in patients with prostate cancer.

blood

Second Opinion™ breast cancer evaluation test

A blood test for patients with abnormal mammograms or lumps that reveals the mutations mostly seen in patients with breast cancer.

CHRONIX NEWS

  • blood-test-could-identify-aggressive-prostate-cancer

Blood test could identify aggressive prostate cancer

The Times

The Times: thousands of men with prostate cancer could be saved from unnecessary operations thanks to a blood test...

  • chronix-biomedical-updates-on-progress-with-prostate-and-pancreatic-cancer-validation-studies

Chronix Biomedical updates on progress with prostate and pancreatic cancer validation studies

Chronix Biomedical

Chronix Biomedical, Inc., a developer of novel cancer blood-based molecular diagnostics, is pleased to update investors on the progress of two clinical studies...

  • cancer-what-you-need-to-know

Cancer – what you need to know?

UK Cancer Research

UK Cancer Research has created Cancer Statistic: Early diagnosis of cancer increases the chances of a full recovery. That's why Advanced Cancer Diagnostics puts attention to the importance of cancer screening. Cancer can’t...

VIDEOS

Prof. Piotr Radziszewski – New generation oncological biomarkers – focusing on Chronix company

Prof. Piotr Radziszewski. New generation oncological biomarkers – focusing on Chronix company. 1.10.2016.

We present a lecture delivered at the 5th Polish women and men health debate according to Medical guidelines – kidney cancer, bladder cancer.

Paul Freiman, Chairman, Chronix – about CNI Tests

#TheTurningPointInCancerFight

Michael Oellerich, MD, Professor of George-August-University Göttingen

#TheTurningPointInCancerFight

ORDER TESTS

Go to Modern Cancer Diagnostics or Advanced Cancer Diagnostics to order our tests

EVENTS

  • laboratory

Advanced Cancer Diagnostics Showcasingat 2016 NCRI Cancer Conference 6-9 November 2016

Chronix Biomedical’s Ireland & UK distributors Advanced Cancer Diagnostics will be attending and showcasing the latest Chronix diagnostic tests: [...]

  • asco-2016

ASCO 2016

“Tumor cell-free DNA copy number instability (CNI) predicts therapeutic response to immunotherapy prior to cycle 2” , was presented [...]

PUBLICATIONS

  • Dr hab. n. med. Jakub Dobruch FEBU - liquid biopsy

Dr hab. n. med. Jakub Dobruch, FEBU – Liquid Biopsy

Dr hab. n. med. Jakub Dobruch, FEBU. Urological Review, The Polish Association of Urology bimonthly magazine. No. 5/2016

Liquid Biopsy is an example of a new kind of research that could revolutionize cancer detection and treatment of patients affected.

Prof. Piotr Radziszewski – New generation oncological biomarkers – focusing on Chronix company

Prof. Piotr Radziszewski. New generation oncological biomarkers – focusing on Chronix company. 1.10.2016.

We present a lecture delivered at the 5th Polish women and men health debate according to Medical guidelines – kidney cancer, bladder cancer.

  • first-published-results-in-breast-cancer

First published results in breast cancer

Beck J, Urnovitz HB, Mitchell WM, Schütz E. Next generation sequencing of serum circulating nucleic acids from patients with invasive ductal breast cancer reveals differences to healthy and nonmalignant controls. Mol Cancer Res 2010; 8:335-42.

Chronix has first used the NGS technology for investigation into the use in breast cancer with very promising results.

DOCTORS ABOUT OUR TESTS

“The knowledge that we have gained over the past year now suggests to us that we are able to provide to doctors and their patients the ability to diagnose at the most earliest stage the presence of cancer in their body.”
Howard Urnovitz, CEO of Chronix Biomedical for The Times
“We believe our cancer blood tests will lead to a world where no one dies unnecessarily of cancer.”
Howard Urnovitz, CEO of Chronix Biomedical